



**World Health
Organization**

INN Working Document 20.472
09/03/2020

Addendum¹ to
***"The use of stems in the selection of International
Nonproprietary names (INN) for pharmaceutical
substances"*** WHO/EMP/RHT/TSN/2018.1

Programme on International Nonproprietary Names (INN)

Medicines and Health Products

World Health Organization, Geneva

© World Health Organization 2020 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.

Addendum¹ to "The use of stem s in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "*The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances*" 2018.

***-caftor* cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers**

bamocafort (121), deutivacafort (118), elexacafort (121), galicafort (119), icenticafort (122), ivacafort (104), lumacafort (105), navocafort (121), nesolicafort (122), olacafort (119), posenacafort (122), tezacafort (114)

***-calcet/-calcet-* calcium-sensing receptors (CaSR) agonists**

cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacalcet (118)

***-cerfont* corticotropin-releasing factor (CRF) receptor antagonists**

crinecerfont (120), emicerfont (102), pexacerfont (97), tildacerfont (119), verucerfont (102)

***-copan* complement receptor antagonists/ complement inhibitors**

avacopan (114), danicopan (119), iptacopan (122), nomacopan (119)

(c) category: pegcetacoplan (120), zilucoplan (118)

***-fexor* farnesoid X receptor agonists**

cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103), vonafexor (122)

-fusp **fusion proteins¹**

bintrafusp alfa (121), cinrebafusp alfa (121), clervonafusp alfa (120), lorukafusp alfa (120), modakafusp alfa (122), onfekafusp alfa (118), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)

-golix **gonadotropin releasing hormone (GnRH) antagonists**

elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

-ixibat **ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors**

barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)

-leuton **5-lipo-oxygenase inhibitors, anti-inflammatory**

atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)

-stat enzyme inhibitors

-becestat **beta-secretase inhibitors**

atabecestat (117), elenbecestat (117), umibecestat (119), lanabecestat (116), verubecestat (112)

-glustat **ceramide glucosyltransferase inhibitors**

duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)

¹ A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting). "Notes from the fusion protein Working Group", INN Working Document number 17.414 rev.

-tinib tyrosine kinase inhibitors

***-ertinib* epidermal growth factor receptor (EGFR) inhibitors**

abivertinib (119), osimertinib (113), epertinib (115), canertinib (87), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), rezivertinib (122), xiliertinib (121), zorifertinib (121)

(b) category: ulixertinib (113), ravoxertinib (115) (Erk inhibitors)

(c) category: afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)

***-tirom(-)* antihyperlipidaemic; thyromimetic derivatives**

acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), resmetirom (119), sobetirome (100)

***-toclax* B-cell lymphoma 2 (Bcl-2) inhibitors, antineoplastics**

obatoclax (94), navitoclax (103), venetoclax (111), imlatoclax (115), pelcitoclax (122), tapotoclax (121), mirzotamab clezutoclax (121), murizatoclax (122)

Amendments were made in the stems' definitions:

-imus

from *immunosuppressants, other than antineoplastics*
to
immunosuppressants, ~~other than antineoplastics~~

-isant

from *histamine H₃ receptor antagonists*
to
histamine H₃ receptor antagonists, inverse agonists

under *-tant*

-netant

from *neurokinin NK3 receptor antagonists*
to
neurokinin NK3 and dual NK3-NK1 receptor antagonists

-pressin

from *vasoconstrictors, vasopressin derivatives*
to
~~*vasoconstrictors,*~~ *vasopressin analogues*

-prim

from *antimicrobials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim ~~derivatives~~*
to
antimicrobials, dihydrofolate reductase (DHFR) inhibitors, trimethoprim analogues

Amendments were made in the target-indicating infix:

-gromab

from *-gros~~m~~ab*
for the designation of INN for monoclonal antibodies targeting skeletal muscle mass related growth factors and receptors